BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 25731482)

  • 1. [Clinical Impact of adjuvant chemotherapy in patients with T1N2/3 Gastric cancer].
    Tsuchida K; Kunisaki C; Watanabe T; Ono H; Oshima T; Fukushima T; Yoshikawa T; Rino Y; Imada T; Masuda M
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):2239-41. PubMed ID: 25731482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Favorable long-term outcomes of one-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer treated at a high-volume center.
    Kano Y; Ohashi M; Hiki N; Takahari D; Chin K; Yamaguchi K; Tsuda Y; Shoji Y; Yasufuku I; Eto K; Ida S; Kumagai K; Nunobe S; Sano T
    Gastric Cancer; 2018 Nov; 21(6):1024-1030. PubMed ID: 29700635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Postoperative adjuvant chemotherapy with S-1 alters recurrence patterns and prognostic factors among patients with stage II/III gastric cancer: A propensity score matching analysis.
    Kanda M; Murotani K; Kobayashi D; Tanaka C; Yamada S; Fujii T; Nakayama G; Sugimoto H; Koike M; Fujiwara M; Kodera Y
    Surgery; 2015 Dec; 158(6):1573-80. PubMed ID: 26120068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine.
    Sakuramoto S; Sasako M; Yamaguchi T; Kinoshita T; Fujii M; Nashimoto A; Furukawa H; Nakajima T; Ohashi Y; Imamura H; Higashino M; Yamamura Y; Kurita A; Arai K;
    N Engl J Med; 2007 Nov; 357(18):1810-20. PubMed ID: 17978289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Factors predictive of recurrence after surgery for gastric cancer followed by adjuvant S-1 chemotherapy.
    Wada T; Kunisaki C; Hasegawa S; Takagawa R; Momiyama M; Kosaka T; Makino H; Ono HA; Oshima T; Akiyama H; Endo I
    Anticancer Res; 2013 Apr; 33(4):1747-51. PubMed ID: 23564827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Examination of continuity of S-1 adjuvant chemotherapy for gastric cancer patients after gastrectomy].
    Kawabata R; Imamura H; Kishimoto T; Anami S; Yasui Y; Fujino M; Fujii C; Sumida R; Furukawa H
    Gan To Kagaku Ryoho; 2011 May; 38(5):793-5. PubMed ID: 21566439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prognosis and clinical course of gastric cancer with para-aortic lymph node metastasis after curative D2 gastrectomy and adjuvant chemotherapy with S-1].
    Aoyama T; Yoshikawa T; Hayashi T; Kuwabara H; Mikayama Y; Ogata T; Cho H; Tsuburaya A; Rino Y; Masuda M
    Gan To Kagaku Ryoho; 2011 Nov; 38(12):2331-3. PubMed ID: 22202372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of S-1 adjuvant chemotherapy on survival following recurrence and efficacy of first-line treatment in recurrent gastric cancer.
    Hasegawa H; Fujitani K; Kurokawa Y; Hirao M; Nakazuru S; Mita E; Tsujinaka T
    Chemotherapy; 2010; 56(6):436-43. PubMed ID: 21088394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Present state and prospects of adjuvant chemotherapy for gastric cancer].
    Hori T; Ozawa R; Hanayama H; Yamashita H; Kaibe N; Matsumoto T; Oshima T; Takemura M; Kikuchi S; Sasako M
    Gan To Kagaku Ryoho; 2011 Sep; 38(9):1390-5. PubMed ID: 21918333
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of body weight loss in gastrectomy patients who underwent only surgery and those who underwent surgery followed up with S-1 adjuvant chemotherapy].
    Aoyama T; Yoshikawa T; Shirai J; Hayashi T; Ogata T; Cho H; Yukawa N; Oshima T; Rino Y; Ozawa Y; Kitani Y; Wada H; Masuda M; Tsuburaya A
    Gan To Kagaku Ryoho; 2012 Nov; 39(12):1794-6. PubMed ID: 23267889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Associations between CYP2A6 polymorphisms and outcomes of adjuvant S-1 chemotherapy in patients with curatively resected gastric cancer.
    Jeong JH; Park SR; Ahn Y; Ryu MH; Ryoo BY; Kong SY; Yook JH; Yoo MW; Kim BS; Kim BS; Kang YK
    Gastric Cancer; 2017 Jan; 20(1):146-155. PubMed ID: 26715117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer.
    Sasako M; Sakuramoto S; Katai H; Kinoshita T; Furukawa H; Yamaguchi T; Nashimoto A; Fujii M; Nakajima T; Ohashi Y
    J Clin Oncol; 2011 Nov; 29(33):4387-93. PubMed ID: 22010012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of Post-Gastrectomy Adjuvant S-1 Chemotherapy on Muscle Volume in Gastric Cancer Patients].
    Iwazawa T; Kawanishi K; Fujita J; Takata A; Hirota M; Imamura H; Ikeda A; Hokonohara K; Yoneyama C; Kameyama A; Shinke G; Oshima K; Tanida T; Hatano H; Noda T; Komori T; Morita S; Akagi K; Dono K
    Gan To Kagaku Ryoho; 2015 Aug; 42(8):957-60. PubMed ID: 26321709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical significance of the human epidermal growth factor receptor 2( HER2) in patients with recurrent gastric cancer who received S-1 adjuvant chemotherapy].
    Aoyama T; Hayashi T; Fujikawa H; Ogata T; Cho H; Wada H; Kitani Y; Yukawa N; Oshima T; Rino Y; Ozawa Y; Masuda M; Yoshikawa T
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):1647-9. PubMed ID: 24393876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The role of adjuvant chemotherapy with S-1 for gastric cancer patients].
    Kitagawa M; Ichikawa D; Okamoto K; Shiozaki A; Fujiwara H; Kuriu Y; Ikoma H; Nakanishi M; Ochiai T; Sakakura C; Kokuba Y; Sonoyama T; Otsuji E
    Gan To Kagaku Ryoho; 2010 Oct; 37(10):1917-9. PubMed ID: 20948256
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial.
    Ito S; Ohashi Y; Sasako M
    BMC Cancer; 2018 Apr; 18(1):449. PubMed ID: 29678146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. S-1 Adjuvant Chemotherapy Earlier After Surgery Clinically Correlates with Prognostic Factors for Advanced Gastric Cancer.
    Yamamoto M; Sakaguchi Y; Kinjo N; Yamaguchi S; Egashira A; Minami K; Ikeda Y; Morita M; Toh Y; Okamura T
    Ann Surg Oncol; 2016 Feb; 23(2):546-51. PubMed ID: 26442923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An increase in the neutrophil-to-lymphocyte ratio during adjuvant chemotherapy indicates a poor prognosis in patients with stage II or III gastric cancer.
    Mori M; Shuto K; Kosugi C; Narushima K; Hayashi H; Matsubara H; Koda K
    BMC Cancer; 2018 Dec; 18(1):1261. PubMed ID: 30558575
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of insulin-like growth factor-1 receptor and amphiregulin expression on survival in patients with stage II/III gastric cancer enrolled in the Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer.
    Ichikawa W; Terashima M; Ochiai A; Kitada K; Kurahashi I; Sakuramoto S; Katai H; Sano T; Imamura H; Sasako M
    Gastric Cancer; 2017 Mar; 20(2):263-273. PubMed ID: 26884344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility study of supportive care using lafutidine, a histamine H2 receptor antagonist, to prevent gastrointestinal toxicity during chemotherapy for gastric cancer.
    Namikawa T; Munekage E; Maeda H; Kitagawa H; Kobayashi M; Hanazaki K
    Anticancer Res; 2014 Dec; 34(12):7297-301. PubMed ID: 25503163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.